Showing results (2041-2050 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|May 16, 2025
TP53 and DNA-PK as potential biomarkers for enhanced efficacy of Olaparib in colorectal cancerDo Yeon Kim, Hyeseon Yun, Ji-Eun You, et al.
Investigational New Drugs|August 20, 2025
Phase 1/2, open-label study of oral bacterial supplementation (EDP1503) plus pembrolizumab in participants with advanced or metastatic microsatellite-stable colorectal cancer, triple-negative breast cancer, and checkpoint inhibitor-relapsed tumorsJudy S Wang, Edward R Arrowsmith, J Thaddeus Beck, et al.
Investigational New Drugs|February 5, 2026
Selective cytotoxicity of solamargine via oxidative stress and caspase-independent mechanisms in human glioblastoma cellsArthur Barcelos Ribeiro, Marcela de Melo Junqueira, Ricardo Andrade Furtado, et al.
Investigational New Drugs|October 28, 2003
The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylationLisa Ann Kraus, Shanti K Samuel, Steven M Schmid, et al.
Investigational New Drugs|October 28, 2003
Immunomodulatory effects of docetaxel on human lymphocytesMing-Sing Si, David K Imagawa, Ping Ji, et al.
Investigational New Drugs|October 28, 2003
Effect of valspodar on the pharmacokinetics of unbound paclitaxelAlbert J ten Tije, Timothy W Synold, Darcy Spicer, et al.
Investigational New Drugs|May 24, 2013
Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysisViswanath Reddy Belum, Shenhong Wu, Mario E Lacouture
Investigational New Drugs|May 29, 2013
Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancerChanghoon Yoo, Min-Hee Ryu, Young-Soon Na, et al.
Investigational New Drugs|May 17, 2013
A randomized, multi-center, open-label, phase II study of once-per-cycle DA-3031, a biosimilar pegylated G-CSF, compared with daily filgrastim in patients receiving TAC chemotherapy for early-stage breast cancerK H Park, J H Sohn, S Lee, et al.
Investigational New Drugs|May 22, 2013
A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2Yousuke Nakai, Hiroyuki Isayama, Hideaki Ijichi, et al.
Pageof 372